Spain

Spain is a cautious but scientifically relevant psychedelic research country. The practical patient-access route is narrow: intranasal esketamine is EU-authorised, listed in Spain, and publicly financed only for a restricted National Health System treatment-resistant depression pathway.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Spain.

1
Spain is not a broad psychedelic-care market. It is a specialist-care jurisdiction with one restricted reimbursed esketamine pathway and a wider research footprint.
2
The main access correction is reimbursement: Spravato is publicly financed in Spain, but only for severe TRD under strict hospital-linked criteria.
3
Off-label ketamine should not be merged with approved psychedelic medicine. It is a separate anaesthetic route with fragmented psychiatric use.
4
Spain has a stronger scientific record than its current access rules suggest, especially in ayahuasca/DMT human pharmacology and early MDMA/PTSD research.
5
Barcelona is the strongest research cluster; Madrid is most important for AEMPS, parliamentary debate and recent ayahuasca litigation.
6
Claims about private ketamine volumes, insurance cover or ayahuasca legality need manual checking because public evidence is incomplete and partly organisational.

Research Snapshot

Blossom currently tracks 24 psychedelic clinical trials connected to Spain, including 4 active studies.

Active trials: 4
Total trials: 24
Stakeholders: 18
Events: 7

Top Compounds

Esketamine(9)
Ketamine(4)
MDMA(4)
Psilocybin(2)
5-MeO-DMT(1)

Active Trial Preview

View all trials →

Medical Access Snapshot

Spain publicly finances Spravato for a narrow severe TRD subgroup through specialist care. Ketamine psychiatric use is off-label and fragmented, while psilocybin, MDMA and other classical psychedelics remain controlled, investigational or exceptional-access only.

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

Spain treats the core classical psychedelics through a restrictive psychotropic-control regime. The consolidated BOE text expressly lists DMT, LSD, MDMA, mescaline, psilocybin and psilocin, and AEMPS oversees psychotropics, narcotics and special access routes. Spravato is authorised and publicly financed for a narrow severe TRD subgroup, while racemic ketamine is an authorised anaesthetic, not an authorised antidepressant. AEMPS special-situations access can support investigational medicines case by case, but it is not a general psilocybin, MDMA or 5-MeO-DMT access programme. Ayahuasca is not an authorised medicine or a national ceremonial exemption; recent court discussion should be treated as a contested legal signal, not nationwide medical access.

History of Research in Spain

Spain still rests on a late-1970s psychotropic-control structure. The 1977 Royal Decree that implemented the 1971 Convention remains the key legal reference for the classical psychedelics now discussed in medical research, including DMT, LSD, MDMA, mescaline, psilocybin and psilocin. That structure helps explain why later activity moved through controlled trials, special access or adjacent medicines rather than ordinary clinical practice. # #

The first modern clinical milestone came in 2000, when a Madrid team led by Jose Carlos Bouso obtained AEMPS approval for a MAPS-funded MDMA-assisted psychotherapy pilot in PTSD. The study was historically important but tiny and short-lived, with later accounts describing early termination after six women had been treated. #

Spain then became especially influential in human psychopharmacology. Around Barcelona and Sant Pau, Jordi Riba and colleagues produced foundational modern work on ayahuasca, including human pharmacology, tolerability and neurophysiology studies. That work gave Spain a lasting role in psychedelic mechanism research without creating legal routine medical use. #

The current clinical-access phase has moved through esketamine and ketamine rather than classical psychedelics. EU authorisation of Spravato in 2019, Spanish public financing from November 2022, and participation in multinational depression studies have moved the national discussion from mechanism science into hospital implementation, pricing and evidence standards. # # # #

Barcelona and Madrid

Barcelona is Spain's clearest psychedelic research node. It combines the historical Sant Pau ayahuasca/DMT programme, visible depression-trial activity, hospital psychiatry, policy organisations and professional networks. The city matters because it links human psychopharmacology with trial infrastructure and implementation debate. # # # #

The Barcelona cluster draws strength from continuity. Sant Pau anchors the historical human pharmacology record; Hospital Clinic-linked investigators appear in current fast-acting antidepressant research; and Parc Sanitari Sant Joan de Deu-related centres appear in public psilocybin trial listings. This is an institutional cluster rather than a single provider story. # # #

Madrid remains important for different reasons. It is the administrative home of AEMPS, the site of the first modern Spanish MDMA/PTSD trial, the venue for the February 2026 parliamentary conference, and the jurisdiction behind the most cited recent ayahuasca ruling. # # # #

Research Focus

Visible interventional work is concentrated in depressive disorders, especially treatment-resistant depression. Spain appears in the COMP006 Phase III psilocybin programme and in newer rapid-acting antidepressant work, while Barcelona-linked investigators appear around the GH001 mebufotenin/5-MeO-DMT Phase IIb publication. Esketamine is the most clinically mature compound because it overlaps with a real, if narrow, access pathway. # # #

Spain also retains a distinctive translational strand. The earlier Sant Pau ayahuasca programme, later observational work and Barcelona-based policy and professional organisations make the country useful for questions about phenomenology, mechanism, tolerability, ethics and context. That research strength should not be mistaken for open prescribing. # # #

The key publication watch items are full follow-up from psilocybin Phase III programmes, development decisions around GH001, and whether Spain-based hospital groups expand trial participation. For now, the evidence base is building faster than the patient-access system is opening. # # #

Key Milestones

1977

Spain adopts the Royal Decree that structures control of psychotropic substances and incorporates core classical psychedelic molecules into national controls.

2000

AEMPS approves the MAPS-funded Madrid MDMA/PTSD pilot, one of Spain's key modern psychedelic clinical milestones.

2001

Spanish investigators publish early human tolerability data on ayahuasca.

2003

The Riba ayahuasca human pharmacology paper helps establish Barcelona as a major psychopharmacology node.

2019

EMA grants EU-wide marketing authorisation to Spravato.

2022

Spain implements restricted public financing for Spravato in severe TRD from 1 November 2022.

2025

A Madrid higher-court ayahuasca ruling becomes a prominent legal reference point, while still falling short of a national medical pathway.

2026

Spain holds its first parliamentary conference dedicated to psychedelic-assisted therapies in the Congress of Deputies.

2026

GH001 Phase IIb TRD results are published, with Barcelona-linked participation and commentary.

Future Outlook

In the next 12-24 months, change in Spain is more likely to come from evidence than from broad access reform. The main watch items are full publication and regulatory follow-up from psilocybin Phase III programmes, replication and development decisions around GH001, and whether Spain-based centres deepen participation in multinational TRD protocols. # #

The Spravato precedent is the most useful guide to future reimbursement. Authorisation does not mean broad funding, and funding does not mean easy access. Any future classical psychedelic with European marketing authorisation would still need Spanish positioning, pricing and delivery decisions, likely with strict severity, prior-treatment and setting conditions. # # #

Professional preparation may move faster than market access. Hospital groups, research teams and societies are already working through protocol, ethics, training and implementation questions, but patient access outside trials will still depend on evidence, authorisation, payer acceptance and trained delivery capacity. # #